NovoCure Ltd. Announces Board Changes and Filings
Ticker: NVCR · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, director-election, filings
Related Tickers: NVCR
TL;DR
NovoCure's board is shaking up: two directors out, two new ones in. Plus, they filed their financials.
AI Summary
NovoCure Ltd. announced on June 5, 2024, a series of significant corporate actions. These include the departure of two directors, Dr. William F. Weldon and Mr. Michael J. Davies, effective June 5, 2024. Concurrently, the company elected two new directors, Ms. Karen L. King and Mr. Michael J. Davies (who rejoined the board), also effective June 5, 2024. Additionally, the company filed its financial statements and exhibits.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding future strategy and leadership, which may affect the company's performance.
Key Players & Entities
- NovoCure Ltd. (company) — Registrant
- Dr. William F. Weldon (person) — Departing Director
- Mr. Michael J. Davies (person) — Departing and Newly Elected Director
- Ms. Karen L. King (person) — Newly Elected Director
- June 5, 2024 (date) — Effective date of director changes
FAQ
Who are the directors departing NovoCure Ltd. and when did their departure become effective?
Dr. William F. Weldon and Mr. Michael J. Davies departed NovoCure Ltd. effective June 5, 2024.
Who has been elected to NovoCure Ltd.'s board of directors?
Ms. Karen L. King and Mr. Michael J. Davies have been elected to NovoCure Ltd.'s board of directors.
When were the new directors elected to NovoCure Ltd.'s board?
The new directors, Ms. Karen L. King and Mr. Michael J. Davies, were elected effective June 5, 2024.
What other items were reported in this 8-K filing besides director changes?
This 8-K filing also includes information regarding the election of directors, appointment of certain officers, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
What is the principal executive office address for NovoCure Ltd. as listed in the filing?
The principal executive offices of NovoCure Ltd. are located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF.
Filing Stats: 969 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-06-10 16:09:16
Filing Documents
- nvcr-20240605.htm (8-K) — 56KB
- novocurelimited2024omnibus.htm (EX-10.1) — 241KB
- 0001645113-24-000016.txt ( ) — 466KB
- nvcr-20240605.xsd (EX-101.SCH) — 2KB
- nvcr-20240605_lab.xml (EX-101.LAB) — 21KB
- nvcr-20240605_pre.xml (EX-101.PRE) — 12KB
- nvcr-20240605_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders At the Annual Meeting, proxies and in-person shareholders representing 85,868,193 shares of the Company's ordinary shares, or approximately 79.8% of the total shares entitled to vote, were present in person or by proxy and voted on the following proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on April 22, 2024. 1. Election of Directors . The ten nominees for election to the Company's Board of Directors were elected as directors to hold office until the Company's 2025 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes: For Against Abstain Broker non-votes Asaf Danziger 70,361,825 548,389 56,464 14,901,515 William Doyle 68,652,398 2,260,141 54,139 14,901,515 Jeryl Hilleman 69,730,284 1,170,038 66,356 14,901,515 David Hung 70,045,127 855,755 65,796 14,901,515 Kinyip Gabriel Leung 69,753,586 1,145,400 67,692 14,901,515 Martin Madden 70,142,778 755,904 67,996 14,901,515 Allyson Ocean 70,077,497 823,634 65,547 14,901,515 Timothy Scannell 69,587,252 1,312,248 67,178 14,901,515 Kristin Stafford 70,144,236 753,901 68,541 14,901,515 William Vernon 69,737,079 1,159,965 69,634 14,901,515 2. Ratification of Independent Registered Public Accounting Firm . The proposal to approve and ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 was approved as an ordinary resolution based upon the following votes: For Against Abstain 80,124,844 5,653,621 89,728 3. Approval of a non-binding advisory vote to approve executive compensation . The proposal to approve executive co
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 NovoCure Limited 2024 Omnibus Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: Jun 10, 2024 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer